Galderma Announces Updates on Nemolizumab Development
2023-10-12 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, October 12, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on October 11 regarding data of phase III clinical studies, in atopic dermatitis (ARCADIA 1/2) and prurigo nodularis (OLYMPIA 1) at EADV (European Academy of Dermatology & Venereology) congress being held in Berlin, Germany, for the humanized anti-human IL-31 receptor A monoclonal antibody nemolizumab, created by Chugai. Clinical development of nemolizumab outside Japan has been conducted by Galderma. Please refer to the link below for details of the Galderma’s press release: Galderma @ EADV 2023: phase III trials demonstrate nemolizumab’s efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis https://www.galderma.com/news/galderma-eadv-2023-phase-iii-trials-demonstrate-nemolizumabs-efficacy-and-rapid-onset-action
The release as fetched from its publisher. chugai-pharm.co.jp ↗